In This Article:
As the U.S. market navigates a period of volatility with investors closely monitoring new tariffs and economic indicators, opportunities for growth can still be found in less conventional areas. Penny stocks, despite their somewhat outdated moniker, remain a relevant investment area for those interested in smaller or newer companies that might offer surprising value. By focusing on penny stocks with strong financial foundations, investors may discover potential long-term opportunities that larger firms often overlook.
Top 10 Penny Stocks In The United States
| Name | Share Price | Market Cap | Financial Health Rating |
| Safe Bulkers (NYSE:SB) | $3.69 | $394.21M | ★★★★☆☆ |
| Tuya (NYSE:TUYA) | $3.03 | $1.89B | ★★★★★★ |
| Cango (NYSE:CANG) | $3.79 | $410.15M | ★★★★★★ |
| Kiora Pharmaceuticals (NasdaqCM:KPRX) | $3.01 | $9.24M | ★★★★★★ |
| Sensus Healthcare (NasdaqCM:SRTS) | $4.73 | $78.68M | ★★★★★★ |
| TETRA Technologies (NYSE:TTI) | $3.36 | $477.94M | ★★★★☆☆ |
| Imperial Petroleum (NasdaqCM:IMPP) | $2.45 | $75.22M | ★★★★★★ |
| BAB (OTCPK:BABB) | $0.81 | $6.1M | ★★★★★★ |
| QuantaSing Group (NasdaqGM:QSG) | $3.08 | $174.81M | ★★★★★★ |
| CBAK Energy Technology (NasdaqCM:CBAT) | $0.7971 | $71.07M | ★★★★★☆ |
Click here to see the full list of 762 stocks from our US Penny Stocks screener.
We'll examine a selection from our screener results.
2seventy bio
Simply Wall St Financial Health Rating: ★★★★★☆
Overview: 2seventy bio, Inc. is a cell and gene therapy company dedicated to researching, developing, and commercializing cancer treatments in the United States, with a market cap of $259.07 million.
Operations: The company generates revenue from its biotechnology segment, amounting to $37.86 million.
Market Cap: $259.07M
2seventy bio, Inc., a cell and gene therapy company, has recently agreed to be acquired by Bristol Myers Squibb for approximately US$286 million. Despite its current unprofitability and decreased revenue from US$100.39 million to US$37.86 million over the past year, the acquisition offers an 88% premium on its recent share price, signaling potential value recognition in its cancer treatment pipeline. The company's short-term assets of US$187.3 million exceed liabilities but do not cover long-term liabilities of US$228.6 million. With no debt and reduced losses over five years, it remains volatile with insider selling noted recently.
Equity Commonwealth
Simply Wall St Financial Health Rating: ★★★★★★
Overview: Equity Commonwealth (NYSE: EQC) is a Chicago-based, internally managed and self-advised real estate investment trust (REIT) focused on commercial office properties in the United States, with a market cap of approximately $173.19 million.